Antibody response is required for protection from Theiler's virus-induced encephalitis in C57BL/6 mice in the absence of CD8+ T cells  by Kang, Bong-Su et al.
www.elsevier.com/locate/yviroVirology 340 (2Antibody response is required for protection from Theiler’s virus-induced
encephalitis in C57BL/6 mice in the absence of CD8+ T cells
Bong-Su Kanga,1, Joann P. Palmaa,1,2, Michael A. Lymana,3,
Mauro Dal Cantob, Byung S. Kima,b,*
aDepartment of Microbiology-Immunology, Northwestern University, Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA
bDepartment of Pathology, Northwestern University, Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA
Received 31 March 2005; returned to author for revision 11 May 2005; accepted 15 June 2005
Available online 21 July 2005Abstract
Intracerebral infection of susceptible mice with Theiler’s murine encephalomyelitis virus (TMEV) induces immune-mediated
demyelinating disease and this system serves as a relevant infectious model for human multiple sclerosis. It was previously shown that
h2M-deficient C57BL/6 mice lacking functional CD8
+ T cells display increased viral persistence and enhanced susceptibility to TMEV-
induced demyelination, and yet the majority of mice are free of clinical signs. To understand the mechanisms involved in this general
resistance of C57BL/6 mice in the absence of CTL responses, mice (AMT) deficient in the B-cell compartment lacking membrane IgM
molecules were treated with anti-CD8 antibody and then infected with TMEV. Although little difference in the proliferative responses of
peripheral T cells to UV-inactivated TMEVand the resistance to demyelinating disease was observed between virus-infected AMTand control
B6 mice, the levels of CD4+ T cells were higher in the CNS of AMT mice. However, after treatment with anti-CD8 antibody, 100% of the
mice displayed clinical gray matter disease and prolonged viral persistence in AMT mice, while only 10% of B6 mice showed clinical
symptoms and very low viral persistence. Transfusion of sera from TMEV-infected B6 mice into anti-CD8 antibody-treated AMT mice
partially restored resistance to virus-induced encephalitis. These results indicate that the early anti-viral antibody response is also important in
the protection from TMEV-induced encephalitis particularly in the absence of CD8+ T cells.
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Institute, 10550 N. Torrey Pine Road, La Jolla, CA 92037, USA.either neutralizing viral infection or other undefined intra-
cellular mechanisms inhibiting viral replication (Burton,
2002; Griffin et al., 1997). However, the precise role of such
antibodies in the protection from and/or pathogenesis of
virus-induced diseases are not well defined as conflicting
results have been reported. For example, in certain viral
systems, it has been reported that antibodies do not play any
significant role in either protection or pathogenesis of CNS
diseases (Burton, 2002; Schneider-Schaulies et al., 2003).
On the other hand, several reports have demonstrated that
antibodies can play a critical role in viral clearance and
consequent protection from developing virus-induced dis-
eases (Burton, 2002; Ramakrishna et al., 2003). Thus, it is
important to dissect the potential role(s) of antibodies in
either protection and/or pathogenesis of a virus-induced
disease under conditions where the effects of other protective005) 84 – 94
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amplified.
A subgroup (including the BeAn8386 and DA strains) of
Theiler’s murine encephalomyelitis virus (TMEV) in the
family of picornavirus (Lipton and Friedmann, 1980; Theiler
and Gard, 1940) causes an inflammatory neurological
demyelinating disease in susceptible mice (Dal Canto and
Lipton, 1975; Lipton and Friedmann, 1980). The TMEV-
induced demyelinating disease system has extensively been
utilized as a relevant infectious animal model of human
multiple sclerosis (MS) because of the chronic and pro-
gressive nature of the disease and close resemblance of
pathogenic mechanisms to human MS. Similarities include
primary demyelination, immune-mediated mechanism in
pathogenesis, presence of oligoclonal CNS Ig and genetic
linkages to bothMHC and TCR genes (Dal Canto et al., 1995;
Dhib-Jalbut and McFarlin, 1990; Oleszak et al., 1995). In
addition, epidemiological studies have supported a potential
role for viruses as the associated agent for MS and this makes
the TMEV system an attractive experimental model (Dal
Canto et al., 1995; Dhib-Jalbut and McFarlin, 1990).
Viral persistence and the level of immune responses to
viral antigens in the CNS of TMEV-infected mice are
associated with the pathogenesis of demyelination (Clatch et
al., 1986; Tangy et al., 1991). Demyelinating lesions are
characterized by an inflammatory cell infiltrate consisting of
predominantly T cells and macrophages (Pope et al., 1996),
and it has now been well established that the pathogenesis of
this virally-induced demyelinating disease is immune-
mediated with the primary involvement of CD4+ Th1-type
cells (Kim et al., 2001). However, it is highly controversial
whether cytotoxic T cells are also involved in the patho-
genesis of demyelination or exclusively in protection from
disease by eradicating virus-infected cells to eliminate the
reservoir of replicating virus (Begolka et al., 2001; Palma et
al., 2001; Rivera-Quinones et al., 1998).
Similarly, the potential role of antibodies to viral epitopes
in the pathogenesis of demyelination induced by TMEV
infection is not yet clear. Antibodies with relatively restricted
heterogeneity are found in the spinal fluids of virus-infected
mice (Roos et al., 1987) as well as in MS patients (Mattson et
al., 1981). Furthermore, B cells producing antibodies to viral
capsid proteins are detectable in the demyelinating lesion
(Cash et al., 1989). In addition, an attempt was made to delete
B cells by neonatal treatment with polyclonal anti-IgM
antibody and found that such treatment enhanced demyeli-
nating disease only in susceptible SJL mice but not in re-
sistant strains (Rodriguez et al., 1990). A time course study
indicated that susceptible SJL mice intracerebrally infected
with TMEV strongly and selectively recognize the
VP1262–276 epitope as compared to resistant BALB/c or
C57BL/6 mice (Inoue et al., 1994). The major detectable
antibodies in the CNS were also against this epitope in
virus-infected SJL mice. Furthermore, susceptible SJL
mice preimmunized with the antibody epitope peptides or
isolated capsid proteins are resistant to TMEV-induceddemyelination (Yahikozawa et al., 1997), suggesting the
protective role of the antibody response to TMEV. How-
ever, the level of antibodies to this particular linear epi-
tope, capable of efficiently neutralizing virus in vitro,
increased with the progression of disease, leaving the door
open for a pathogenic role. In addition, it has been shown
that a monoclonal antibody to TMEV VP1 cross-reacts
with galactocerebroside on the myelin and oligodendro-
cytes, suggesting a pathogenic role of such antibodies.
Therefore, the potential role of such antibody responses in
the pathogenesis and protection is not yet well understood.
In this report, we have determined the potential role of the
antibody response in TMEV-induced demyelinating disease
using AMT mice on a B6 background that are known to be
deficient in antibody responses. B6 mice are exceptionally
resistant to TMEV-induced demyelinating disease and dis-
play very efficient virus-specific CD8+ T cell response for
viral clearance in the CNS compared to susceptible SJL/J
mice (Lyman et al., 2004). Thus, assessment of resistance to
TMEV-induced demyelinating disease in AMT mice with/
without CTL responses would provide valuable information
regarding the potential role of the antibody response. Our
results indicate that all the AMT mice treated with anti-CD8
antibody showed prolonged viral persistence and clinical
disease, whereas very few, if any, treated B6 mice or
untreated AMT mice did the same. However, the absence of
anti-viral antibodies, in combination with the deficiency in
the CD8+ T cell compartment, renders viral encephalitis
rather than demyelinating disease. These results indicate the
presence of a hierarchy of protective immune responses. The
protection by the CD8+ T cell response supersedes the
antibody response and this T cell response is sufficient in
rendering resistance to TMEV-induced demyelination.
Nevertheless, the presence of antibodies specific for TMEV
may be able to lower the level of viral persistence to a degree
preventing encephalitis in the absence of CTL. These results
suggest that both anti-viral antibodies and CTL are involved
in viral clearance for protection from TMEV-induced disease
and these are likely to function synergistically.Results
Antibody deficient B6 mice are resistant to TMEV-induced
demyelinating disease
To assess the potential role of antibodies to TMEV in
protection from TMEV-induced demyelinating disease, B
cell-deficient B6 mice (AMT) lacking membrane IgM
molecules were infected with TMEV and compared to
wildtype B6mice. No detectable clinical signs were observed
in either group (10 each) infected with TMEV for up to 150
days (data not shown). The results of histological examina-
tion were consistent with the lack of clinical signs. No
inflammation or demyelinating lesions were present in either
gray or white matter in the CNS of wildtype B6 or AMTmice
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clearly indicate that AMTmice deficient in antibody response
are similarly resistant to TMEV-induced demyelinating
disease.
Peripheral immune responses to TMEV are reduced in lMT
mice compared to wildtype
To verify the deficiency in the antibody response in AMT
mice compared to that in the wildtype B6 mice infected with
TMEV, antibody levels reactive to viral antigens in the sera
from mice infected for 14 days were assessed by ELISA (Fig.
1A). The results clearly indicate that virus-infected AMT
mice are not capable of producing antibodies reactive to
TMEVantigens, while such viral infection to the wildtype B6
mice results in detectable anti-viral antibody production. The
levels of natural antibodies reactive to TMEV in uninfected
mice were insignificant. To further determine whether T cell
responses to TMEV antigens in the periphery are intact inFig. 1. Comparison of peripheral immune responses to viral antigens in AMT
and B6 mice infected with TMEV. (A) Antibody levels specific for TMEV in
the pooled sera from 4 mice infected for 14 days were assessed by ELISA.
The differences between B6-ic and AMT-ic differ significantly (Two-tailed P
value by the paired t test is 0.0288). (B) Proliferative responses of splenic T
cells from 3 mice against UV-TMEVand predominant CD4+ T cell epitope
peptides were assessed at 14 days post-infection by 3H-TdR uptake assays.
The level of proliferative Tcell responses to the viral epitopes is significantly
lower in mMT mice compared to that of B6 mice (P < 0.05).AMT mice infected with TMEV, T cell proliferative response
to UV-TMEV, reflecting the levels of Th responses, were
examined (Fig. 1B). The level of T cell proliferative
responses to TMEV antigens measured with UV-TMEV
and predominant epitope peptides (Kang et al., 2005) was
lower in virus-infected AMT mice. These data suggest
impaired peripheral CD4+ T cell responses to viral antigens
in TMEV-infected AMT mice compared to that of similarly
infected B6 mice.
Early CNS-infiltration of CD4+ T cells, but not CD8+,
is increased in lMT mice
In order to assess the levels of TMEV-specific T cell
responses in the CNS, infiltrating mononuclear cells isolated
from the brains and spinal cords of AMTand control B6 mice
were analyzed for the infiltration levels, virus-specificity as
well as cytolytic function at 10 and 30 days post-infection
(Fig. 2). Interestingly, the overall CD4+ T cell infiltration
level is consistently higher in AMT mice at both time points,
although the level is significantly reduced (from 10% to
1.7%) at day 30 (Fig. 2A). The level of CD4+ T cell
infiltration at 10 days post-infection between AMT and B6
mice from three separate experiments is statistically different
(P < 0.01; 17.5 T 1.5  104 vs. 5.8 T 1  104). However, the
infiltration level of CD8+ Tcells in the CNS of AMTmice was
similar to that of B6 mice at day 10 (11.7 T 2.3 104 vs. 9.3 T
1.8 104) but somewhat increased at day 30 (P = 0.05; 5.3 T
1.2  104 vs. 1.9 T 0.8  104). The infiltration levels of B
(B220+) cells and macrophages/microglia (CD11b+) were
also assessed (Fig. 2B). Small but detectable levels (1.6% at
day 10 and 0.4% at day 30) of B cells were found in the CNS
of B6 mice and none (0.1%) in AMT mice. In contrast, the
level of macrophages/microglia appeared to be higher in
AMT especially at 30 days post-infection. However, the
differences in these cell types were consistent but not reached
to a statistically significant level. The function of CNS-
infiltrating CD8+ T cells specific for viral epitopes were
further assessed based on IFNg production (Figs. 2C and E)
and cytolytic function (Fig. 2D). Similar proportions of CD8+
Tcells in AMTand B6 mice produced IFNg upon stimulation
with the predominant epitope peptide at both time points.
Also, these T cells displayed similar cytolytic function
towards specific epitope-loaded target cells. However, a
higher number of CD8+ and CD4+ T cells specific for viral
epitopes were detected in the CNS of AMT mice (Fig. 2E),
probably reflecting higher levels of T cell infiltration (Fig.
2A) and viral persistence in the B cell-deficient AMT mice
(not shown).
Treatment with anti-CD8 antibody renders lMT mice
susceptible to TMEV-induced encephalitis
To determine whether antibody can play an important role
in the protection from TMEV infection in the absence of
virus-specific CTL responses, AMT mice were repeatedly
Fig. 2. Comparison of lymphocyte infiltration to the CNS and specificity of infiltrating T cells to viral determinants in TMEV-infected AMT and control mice.
Pooled CNS-infiltrating cells from 4 to 5 mice per experimental group were analyzed. (A) CD4+ and CD8+ T cells infiltrating the CNS at 10 and 30 days post-
infection. (B) Macrophages and B cells in the CNS at 10 and 30 days post-infection. (C) IFNg production (flow cytometry) by CNS-infiltrating CD8+ T cells
specific for the major viral determinant at 10 and 30 days post-infection. (D) Cytolytic function of CNS CD8+ T cells towards the predominant CD8+ T cell
determinant at 10 days post-infection. (E) Virus-specific CNS CD8+ and CD4+ T cells producing IFNg (ELISPOT) at 10 days post-infection. A representative
of 3 separate experiments is shown.
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8 and 14 days) viral infection (Fig. 3). In contrast to virus-
infected AMT mice treated with the IgG2b isotype control,
100% of mice treated with anti-CD8 antibody exhibitedFig. 3. Development of neurological disease in TMEV-infected AMT mice
following treatment with anti-CD8 antibody. (A) Disease course of AMT
and control wildtype mice treated with either isotype control or anti-CD8
antibody (9 mice per each group). Data are represented as percent mice
affected with a score of 1 or greater. B6 anti-CD8 vs. AMT anti-CD8, P <
0.05; and AMT-isotype vs. AMT anti-CD8 were P < 0.01 by ANOVA test.
Paired t test, the mean of the differences between AMT-isotype vs. AMT
anti-CD8 differ significantly; the two-tailed P value is 0.0394. The mean of
the differences between B6 anti-CD8 and AMT anti-CD8 differ signifi-
cantly; the two-tailed P value is 0.0414. (B) Histopathological evidence for
encephalitis in anti-CD8 antibody-treated AMT mice. Section from a spinal
cord of isotype control Ig-treated AMT mouse 50 days after infection shows
normal histology of the anterior horn and white matter. Section from spinal
cord of AMT mouse treated with anti-CD8 antibody shows mild to
moderate inflammatory infiltration of the anterior horns. One micron thick,
Epon embedded section, stained with toluidine blue.clinical signs similar to that of demyelinating disease at 35
days post-viral infection (Fig. 3A). However, only one of 10
B6 mice treated with the antibody showed very mild
symptoms compared to anti-CD8 antibody-treated AMT
mice. These results clearly indicate that the presence of
antibody response is critically important for protection from
developing clinical neurologic disease in resistant B6 back-
ground when CD8+ T cell responses are compromised.
To further analyze the nature of the neurological symp-
toms developed in anti-CD8 antibody-treated AMT mice
following TMEV infection, histopathologic examination of
the spinal cords from isotype- and anti-CD8 antibody-treated
AMT mice were performed at 50 days post-TMEV infection
(Fig. 3B). Isotype control IgG-treated mice free of clinical
symptoms displayed intact histologic architecture of the
anterior horn and white matter. In contrast, clinically affected
anti-CD8 antibody treated AMT mice showed mild to
moderate inflammatory infiltration in the anterior horns
characteristic of gray matter disease and yet demyelination
characteristic of white matter disease was not apparent.
Therefore, these results strongly suggest that the antibody
response to TMEV is critically important in preventing viral
encephalitis (gray matter disease), particularly when mice are
deficient in CD8+ cytotoxic T cell responses. However, the
intact CD8+ T cell response in the absence of antibody
response appears to be sufficient for protection from TMEV-
induced encephalitis and demyelinating disease in mice with
B6 background.
Viral persistence and chemokine gene activation is
enhanced in lMT mice following treatment with anti-CD8
antibody
To correlate the above clinical symptoms and immune
responses in the CNS with the level of viral persistence,
replicating virus particles recovered from the CNS from these
animal groups were compared at 45 days post-viral infection
(Fig. 4). C57BL/6 mice treated with anti-CD8 antibody
showed significantly increased (>20 fold) viral titers in the
CNS compared to isotype-treated control mice (Fig. 4A).
Interestingly, isotype-treated AMT mice also displayed
increased viral persistence above (>100 and >3 fold,
respectively) that seen in isotype- and anti-CD8 antibody-
treated B6 mice. These results clearly demonstrate that viral
persistence is significantly enhanced in AMT mice compared
to the wildtype B6 counter part and yet such an elevation of
viral persistence alone is not sufficient to succumb to clinical
disease (Fig. 3). Finally, anti-CD8 antibody-treated AMT
mice exhibited a further increase in viral titers over isotype-
treated AMT and anti-CD8 antibody-treated B6 mice (>13
fold and >50 fold, respectively). Interestingly, the viral titers
found in the CNS of anti-CD8 antibody-treated AMT mice
exceeded (>2 fold) the level seen in highly susceptible SJL
mice at a late stage (50 days) of viral infection. The levels of
inflammatory responses measured by chemokine gene ex-
pression and viral messages in the CNS using RPA, parallel
Fig. 4. Comparison of viral persistence and chemokine messages in the CNS of AMT and B6 mice treated with isotype control or anti-CD8 antibody. (A) Viral
persistence in the CNS of mice determined by plaque assays. The CNS pooled from 5 mice per group at 45 days post-infection was analyzed. The mean and
SEM of triplicate determinations of plaque forming units are shown. Note that viral persistence in AMT mice treated with anti-CD8 antibody exceeded the level
in highly susceptible SJL/J mice. B6 anti-CD8 vs. AMTanti-CD8, P < 0.001; B6 anti-CD8 vs. SJL, P < 0.001; AMT isotype vs. AMTanti-CD8, P < 0.001; and
AMT anti-CD8 vs. SJL were P < 0.001 by ANOVA test. (B) RNase protection assay of chemokine gene expression in the CNS of virus-infected mice.
Chemokine gene expression in pooled brains and spinal cords (5 mice) was analyzed by RPA at 50 days post-infection. CON, control naive mice; ISO, mice
treated with isotype control antibody and TMEV infected; and aCD8, mice treated with anti-CD8 antibody and TMEV-infected.
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found in the CNS of anti-CD8-treated AMT, an intermediate
level in isotype-treated AMT and undetectable levels in anti-
CD8 or isotype-treated B6 mice. These results indicate that
the antibody response to TMEV plays an important role in
controlling viral persistence and reducing inflammatory
responses in the CNS, particularly in the absence of the
CD8+ T cell response.
Increased CD4+ and reduced CD8+ T cell infiltration is
found in the CNS of lMT mice compared to B6
To correlate susceptibility to TMEV-induced encephalitis
in anti-CD8 antibody treated AMT mice with the cellular
infiltration in the CNS, infiltrating mononuclear cell pop-
ulations in the CNS of antibody-treated mice were compared
to those of control mice treated with isotype-matched IgG by
flow cytometric analyses at 45 days post-infection (Fig. 5).
Interestingly, CD4+ T cells were significantly greater (3–4
fold) than CD8+ T cells in the CNS of isotype-treated AMT
mice compared to B6 mice (Fig. 5A). However, the CD4+/
CD8+ T cell ratio in isotype-treated B6 mice was reversed
(4% vs. 9%). As expected, the anti-CD8 antibody treatment
resulted in a significant reduction in the levels of CNS-
infiltrating CD8+ T cells in both AMT and control C57BL/6
mice. These results clearly indicate that the CD4+ T cell
population is relatively higher than CD8+ T population in
AMT mice compared to B6 mice and anti-CD8 antibody
treatment has successfully eliminated the accumulation of
CD8+ T cells in the CNS.
To further analyze the specificity of the CNS infiltrating
cells in the antibody-treated AMT mice, the levels of TMEV-specific T cell responses were assessed (Fig. 5B). Cells
producing IFNg in response to the predominant and sub-
dominant CD8+ T cell epitopes (VP2121–130 and VP2161–180,
respectively) and recently identified CD4+ T cell epitopes
(VP2201–220 and VP421–40) were enumerated by ELISPOT
assays. The results indicate that the reduction of CD8+ T cell
infiltration to the CNS in anti-CD8 antibody treated mice also
leads to a significant reduction of TMEV-specific CD8+ T
cells in the CNS and periphery. However, there is no
significant difference in the levels of virus-specific CD4+ T
cells between the CNS of mice treated with isotype IgG and
anti-CD8 antibody. It is interesting to note that the overall
CNS infiltration of CD4+ T cells is increased in AMT mice
(Fig. 5A) and yet the population contains a similar level of
virus-reactive CD4+ T cells. The reactivity of the non-virus-
specific CD4+ T cells is not yet known. Nevertheless, these
results show that treatment of mice with anti-CD8 antibody
efficiently reduces the number of CD8+ T cells in the CNS
and periphery, including virus-specific CD8+ T cells. Thus,
the antibody treatment appears to selectively reduce the CD8+
T cell responses without compromising the virus-specific
CD4+ T cell responses in the CNS of these mice.
Antibodies from TMEV-infected B6 mice protect anti-CD8
antibody-treated lMT mice from developing encephalitis
In order to verify the protective role of antibodies against
TMEV in the absence of CD8+ T cell response, pooled sera
from naive B6 or B6 mice infected with TMEV for 14 days
were transfused into anti-CD8 antibody-treated AMT mice
and then intracerebrally infected with TMEV (Fig. 6). Mice
receiving immune sera significantly delayed the develop-
Fig. 5. Analysis of peripheral and CNS-infiltrating T cells in AMT and B6 mice treated with isotype control or anti-CD8 antibody at 45 days post-TMEV-
infection. Pooled T cells from the CNS and periphery of 5 mice per group were analyzed. (A) Flow cytometric analyses of CD4+ and CD8+ T cells in the CNS
and periphery of mice. (B) ELISPOT determination of IFNg-producing T cells in the CNS and periphery of virus-infected mice upon stimulation with viral
epitopes. A representative of three similar experiments is shown here.
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mouse sera. These results clearly indicate that antibodies to
TMEV can provide a significant protection from virus-
mediated encephalitis in resistant mouse strains and such
protection can be clearly demonstrated in the absence of
CD8+ T cell responses, the dominant immunity in clearing
viral persistence.Discussion
Elevated antibody responses are seen in the CNS as well
as in the periphery of susceptible mice undergoing
demyelinating disease compared to TMEV-infected resistantmice (Inoue et al., 1994). However, the elimination of B
cells from such susceptible mice by neonatal treatment with
anti-Ig antibody showed exacerbated disease as compared to
resistant mice (Rodriguez et al., 1990). Thus, it is still
unclear whether the antibody response to TMEV is
protective and/or pathogenic in developing demyelinating
disease. To further understand the potential role of antibody
response in TMEV-induced demyelinating disease, we have
utilized AMT mice deficient in antibody response in the
presence or absence of CTL response in resistant B6 mice.
We have demonstrated here that the antibody response to
TMEV plays a significant role in preventing virus-induced
encephalitis by facilitating in viral clearance. Although
dispensable in the presence of CD8+ T cell response, the
Fig. 6. Protection from TMEV-induced encephalitis by antibody transfusion
into anti-CD8 antibody-treated AMT mice. A pooled serum from TMEV-
infected B6 mice (20 days after TMEV infection) or serum from naive B6
mice was transfused into AMT mice treated with anti-CD8 antibody at 4, 10
and 20 days after TMEV infection. The disease course was assessed based
on the criteria described in Materials and methods and the clinical scores
represent the average of symptoms of the entire individual mice in each
group without excluding unaffected mice. The two-tailed P value by paired
t test is <0.0001, indicating that the difference of the disease courses of
these groups of mice is extremely significant. A representative of three
separate experiments is shown here.
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the CTL response to the virus is compromised.
The CTL response to the virus alone without antibody
response is sufficient for maintaining resistance to TMEV-
induced neuroinflammatory disease in mice with resistant B6
background as demonstrated with B cell-deficient AMTmice
(Fig. 1). When the intact CTL response is present in virus-
infected AMT mice, no clinical symptoms develop in these
mice. However, viral persistence in these mice is significantly
increased compared to virus-infected B6 mice (Fig. 5).
Resistance to the development of demyelination and clinical
signs in AMT mice is consistent with the previous study
indicating that neonatal anti-IgM antibody treatment has no
apparent effects in resistant mice infected with TMEV
(Rodriguez et al., 1990). The role of antibody response in
the protection appears to be different depending on the degree
of the host susceptibility to virus. For example, both AMTand
B6 mice infected with another neurotropic virus, mouse
Hepatitis virus (MHV) showed clinical symptoms although
the wildtype mice recovered from the acute CNS disease (Lin
et al., 1999). Thus, cell-mediated immune responses alone
appear to be insufficient for protection against this virus,
suggesting a greater importance of antibody response in
controlling MHV infection compared to TMEV infection.
These results suggest that the degree and type of immune
responses required for protection from pathogenesis of
demyelinating disease is different depending on the virus.
Several reports on studies with AMT mice have shown
conflicting results for the levels of T cell responses in these
mice, ranging from severe reduction to near normal responses(Bergmann et al., 2001; Epstein et al., 1995; Phillips et al.,
1996). Although a significant reduction in CD4+ T cell
responses to other viral infection such as LCMV has been
noted, priming and expansion of virus-reactive CD8+ T cells
are relatively intact (Asano and Ahmed, 1996). However, the
CD8+ T cell response to MHV in AMT mice is significantly
reduced as compared to the wildtype B6 mice (Bergmann et
al., 2001). In contrast, similar total numbers of CD8+ T cells
infiltrate the CNS of both these mice infected with TMEV
(Figs. 2 and 5). The potential differences between TMEVand
HMV may be due to the level of CD8+ T cell responses
against these viruses and/or CD4+ T cell dependence. The
level of CD4+ T cell response to TMEV epitopes in the
periphery appears to be lower in AMT mice compared to B6
mice (Figs. 1B and 5), consistent with that in mice infected
with other viruses (Bergmann et al., 2001; Homann et al.,
1998). It is unlikely that the absence of B cells in AMT mice
provide fewer APC than WT mice leading to lower CD4+ T
cell response to TMEVepitope peptides in the periphery (Fig.
1), since antigen presentation of whole protein but not
peptides is compromised in AMT B cells (Constant et al.,
1995). However, significantly higher levels of CD4+ T cells
infiltrate the CNS of TMEV-infected AMT mice than B6
mice. The significance of this increase in the CD4+ T cells in
the CNS for the pathogenesis is not clear. Perhaps, the
increase in the viral persistence in the absence of antibody
response in AMT mice may have resulted in vigorous
stimulation and migration of CD4+ T cells specific for viral
epitopes and/or autoantigens to the site of viral persistence,
CNS, especially during late stages of viral infection.
To examine whether the CD8+ Tcell response to TMEV is
sufficient for protection from developing clinical symptoms
following viral infection in AMT mice, B6 and AMT mice
were repeatedly treated with monoclonal anti-CD8 antibody.
The results clearly indicated that the lack of both antibody
and CD8+ T cell responses, as shown with AMT mice treated
with anti-CD8 antibody, severely compromised the ability to
clear virus from the CNS (Fig. 4), and led to the manifestation
of clinical symptoms in all the treated mice (Fig. 3). Perhaps,
deficiencies in both antibody and CTL responses to the virus
reach a critical threshold where viral replication and patho-
genesis resulting in the development of clinical disease could
not be effectively contained. However, deficiency in the
CD8+ T cell response alone, as shown with B6 mice treated
with anti-CD8 antibody results in only a marginal level of
clinical disease (¨10%). The relative resistance to TMEV-
IDD in B6 mice treated with anti-CD8 antibody is similar to
the previous reports with h2M- or perforin-deficient mice
(Palma et al., 2001; Pullen et al., 1993). It appears that a
significant reduction of the T cell population to a certain
threshold without a complete deletion of CD8+ T cells is
sufficient to drastically alter susceptibility to TMEV-induced
encephalitis. Thus, the antibody response in the absence of
CD8+ T cell response to viral epitopes appears to be critically
important in both viral clearance and resistance to clinical
disease.
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developed in the absence of both antibody and CTL
responses are primarily due to gray matter damage by viral
infection rather than the white matter demyelination (Fig. 3).
This is different from the disease in CD8+ T cell-deficient
mice, which display extensive demyelination in the white
matter (Pullen et al., 1993; Rodriguez et al., 1993). This
difference may reflect a deficiency in controlling rapid viral
replication due to the absence of both antibody and CTL
responses in AMT mice treated with anti-CD8 antibodies
(Fig. 4). Infection with rapidly replicating neurovirulent
GDVII TMEVresults in a similar gray matter disease without
demyelination (Sethi and Lipton, 1981), supporting develop-
ment of such encephalitis when deficient in controlling rapid
viral replication. The potential role of antibodies to viral
epitopes in the pathogenesis of demyelination is not yet clear.
Antibody response to viral epitopes in the absence of CD8+ T
cell response may be able to clear the majority of viral
infection, but may not be sufficient for eliminating residual
viral persistence, which subsequently leads to Th1-associ-
ated immune-mediated demyelinating disease. However, it is
also conceivable that certain antibody responses to viral
epitopes may be able to contribute to development of
demyelinating disease by prolonging residual viral persis-
tence via inefficient clearance or masking CTL recognition,
particularly when the host may not be able to mount strong
CD8+ T cell responses. Our recent studies comparing the
levels of TMEV-specific CD8+ T cell responses in the CNS
of susceptible SJL/J and resistant B6 mice, indicated that
susceptible SJL mice generate significantly lower level (3
fold) of virus-specific CD8+ T cells than resistant B6 mice
(Lyman et al., 2004). Therefore, an insufficient level of CD8+
Tcell responses to the virus in susceptible SJL mice owing to
the inefficient viral clearance by antibodies alone may permit
persistent chronic viral infection in the CNS leading to
demyelinating disease. Taken together, these studies indicate
that the importance of antibodies in clearing virus persistence
and protecting from virally induced CNS diseases signifi-
cantly differs between the viruses. Thus, the potential
contribution of antibodies to persistent virus infection may
have to be determined in the absence of the predominat
protective immunity and such determination may provide
important insights on the protective or pathogenic mecha-
nisms involved in virus-induced demyelinating disease. Our
results here with the TMEV system indicate that the presence
of antibodies to viral determinants contributes to the
protection from rather than pathogenesis of disease seconda-
rily to the efficient CD8+ T cell immunity to the virus.Materials and methods
Animals
Inbred mouse strains (C57BL/6 or B6) were purchased
from the Charles River Laboratories (Charles River, MA)via National Cancer Institute and housed at the animal
facility of the Center for Comparative Medicine, North-
western University in compliance with all Animal Care and
Use Committee guidelines. The IgM transmembrane defi-
cient AMT (B6.129S2-Igh-6tm1Cgn) mice in B6 background
(Kitamura et al., 1991) were purchased from the Jackson
Laboratories (Bar Harbor, Main).
Virus preparation and injection
TMEV BeAn 8386 strain was propagated in BHK-21
cells in Dulbecco’s modified Eagle medium supplemented
with 7.5% donor calf serum and the cell lysate was used as a
viral stock for inoculation. TMEV was further purified from
similar cell lysates by centrifugation on sucrose gradients as
described previously and used as viral antigen in vitro
assays (Yauch and Kim, 1994). For intracerebral inoculation
of virus, 1–5  105 PFU TMEV in 30 Al of Dulbecco’s
modified Eagle medium was administered in the right
cerebral hemisphere of mice anesthetized with methoxy-
flurane or isoflurane. Clinical symptoms of disease were
assessed weekly on the following grading scale: grade 0 =
no clinical signs; grade 1 = mild waddling gait; grade 2 =
moderate waddling gait and hind limb paralysis; grade 3 =
severe hindlimb paralysis; grade 4 = severe hindlimb
paralysis and loss of righting reflex; grade 5 = death.
ELISA for the detection of UV-inactivated TMEV
Antibodies specific for viral epitopes were measured
by using indirect enzyme-linked immunosorbent assay
(ELISA). Briefly, 0.3 Ag of total UV-inactivated virus were
used to coat microtiter plates. A bovine serum albumin
solution was also used to coat the plates to serve as a
negative control, and this background reaction was sub-
tracted from experimental values. Unless otherwise stated,
duplicates of 2 fold serial dilutions of pooled sera, starting
from a 1:50 dilution, were applied followed by secondary
goat anti-mouse IgG antibody conjugated with alkaline
phosphatase. After the plates were washed, substrate ( p-
nitrophenyl phosphate) for the enzyme was added and the
enzyme reaction was colorimetrically measured in an
ELISA reader at 405 nm. The average value was shown
in the results.
T-cell proliferation assay
Spleen cells (6  105 cell/well) were cultured in 96-
well flat-bottom plates in RPMI-1640 containing 0.5%
syngeneic mouse serum and 5  105 M 2-mercaptoetha-
nol. Triplicate cultures were stimulated with 1–3 Ag of
UV-inactivated purified virus for 72 h. Cultures were then
pulsed with 1 ACi of 3H-TdR and harvested 18h later.
Measurement of 3H-TdR uptake by the cells were deter-
mined in a scintillation counter and expressed as counts
per minute.
B.-S. Kang et al. / Virology 340 (2005) 84–94 93Isolation of CNS infiltrating lymphocytes
Mice were perfused through the left ventricle with 30ml of
sterile Hank’s balanced salt solution (HBSS). Excised brains
and spinal cords were forced through nylon mesh and
incubated at 37 -C for 45 min in 250 Ag/ml of collagenase
Type IV (Worthington Biochemical Corp., Lakewood, NJ).
CNS-infiltrating lymphocytes were then enriched on a
continuous Percoll (Pharmacia, Piscataway, NJ) gradient
after centrifugation for 30 min at 27,000g.
CTL assay
Brains, spinal cords and spleens were removed 10 days
post-viral infection and assayed in vitro for cytolytic activity
using a standard chromium release assay. Peptide-loaded EL-
4 cells were used as target cells. Effector and target cells were
incubated together in triplicate wells at 100:1, 50:1, 25:1,
12.5:1 E/T ratio. After 5-h incubation, 70 Al of supernatant
was harvested and assayed for released radioactivity. Specific
chromium release was calculated for each well using the
formula [(sample release spontaneous release) 100/(total
release  spontaneous release)]. Values for total and
spontaneous release were obtained by incubation of target
cells with or without 5% Triton-X, respectively.
ELISPOT assay
ELISPOT plates (Millipore, Bedford, MA) were pre-
coated with 1 Ag/ml of anti-IFN-g antibody in 0.05 M
carbonate-bicarbonate buffer pH 9.6. Plates were washed and
then blocked with sterile PBS containing 1% BSA. Plates
were incubated with 2  104 CNS-infiltrating monocytes
plus 1  106 naive syngeneic spleen cells (3000 rads) in 200
Al HL-1 medium (Bio-Whittaker, Walkersville, MD) at 37 -C
under 5% CO2 for 18 h with 2 AM peptide. IFN-g spots were
developed as previously described using biotin-conjugated
anti-IFN-g antibody (Endogen, Boston, MA) and streptavi-
din-HRP in 1% BSA-PBS (Targoni and Lehmann, 1998).
Flow cytometric analysis
Spleen cells or CNS-infiltrating cells were analyzed
immediately after isolation. Cells were incubated in 100 Al
of 2.4G2 hybridoma (ATCC) supernatant for 20 min at 4 -C
to block Fc receptors. Appropriate PE- or FITC-labeled
antibodies were added, and cells were incubated for an
additional 30 min at 4 -C. After two washes, cells were
analyzed on a FACS Calibur flow cytometer. Live cells were
gated based on light scatter properties and exclusion of
propidium iodide.
RNase protection assay
Total RNAs were isolated from the brains and spinal cords
from either uninfected or TMEV-infected mice using Trizol(Gibco, NY) as specified by the manufacturer. The RPA
multiprobe set for chemokines from Pharmingen (CA) were
used to quantitate message levels according to manufactur-
er’s instructions. RNA samples hybridized at 56 -C for 14 h
were then analyzed on a 5% denaturing polyacrylamide gel
and exposed on film for 6–12 h or by phosphor imaging and
subsequently analyzed using the Quantity One Software
(BioRad, CA).
Plaque assay
After cardiac perfusion with cold HBSS, brain and spinal
cords were homogenized in PBS as a 10% (w/v) solution
using a tissue homogenizer and clarified by low-speed
centrifugation (600g). A standard plaque assay was
performed on BHK-21 cell monolayers (Pullen et al.,
1995). Plaques in the BHK monolayer were visualized by
staining with 0.1% crystal violet solution.
Antibody treatments
Mice were injected with monoclonal anti-CD8 (H35-
17.2) or isotype control (IgG2b) antibody (300 Ag/mouse) at
1, 4 and 7 days post-TMEV infection to test the role of
CD8+ T cells in AMT mice. In order to assess the effects of
neutralizing antibody in AMT mice treated with anti-CD8
antibody, a pooled anti-TMEV polyclonal serum or normal
serum from TMEV-infected C57BL/6 mice (20 days after
TMEV infection) and naive mice was transfused into the
antibody-treated group at 4, 10 and 20 days after TMEV
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